Compounds > 3-hydroxy-3-methylglutaryl-coenzyme a

3-hydroxy-3-methylglutaryl-coenzyme a and Dyslipidemias

3-hydroxy-3-methylglutaryl-coenzyme a has been researched along with Dyslipidemias in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Abd Allah, EF; Ambwani, S; Charan, J; Gupta, VK; Hashem, A; Kashyap, P; Kumar, A; Panwar, A; Purohit, A; Ram, H; Riyad, P; Singh, G	1
Banach, M; Jones, SR; Kapoor, K; Martin, SS; Sathiyakumar, V; Toth, PP	1
Giampietro, O; Matteucci, E	1
Belazi, D; Dickson, M; Meissner, B; Reeder, CE; Senevirante, V; Shinogle, J	1

Reviews

2 review(s) available for 3-hydroxy-3-methylglutaryl-coenzyme a and Dyslipidemias

Article	Year
Novel Therapeutic Targets for Managing Dyslipidemia. Trends in pharmacological sciences, 2018, Volume: 39, Issue:8 Topics: Acyl Coenzyme A; Angiopoietin-like Proteins; Animals; Apolipoproteins C; Atherosclerosis; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Molecular Targeted Therapy; Prospective Studies	2018
Statin intolerance: why and what to do - with a focus on diabetic people. Current medicinal chemistry, 2013, Volume: 20, Issue:11 Topics: Acyl Coenzyme A; Animals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors; Signal Transduction	2013

Other Studies

2 other study(ies) available for 3-hydroxy-3-methylglutaryl-coenzyme a and Dyslipidemias

Article	Year
Ameliorations in dyslipidemia and atherosclerotic plaque by the inhibition of HMG-CoA reductase and antioxidant potential of phytoconstituents of an aqueous seed extract of Acacia senegal (L.) Willd in rabbits. PloS one, 2022, Volume: 17, Issue:3 Topics: Acacia; Acyl Coenzyme A; Animals; Antioxidants; Chromatography, Liquid; Dyslipidemias; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Molecular Docking Simulation; Plant Extracts; Plaque, Atherosclerotic; Rabbits; Senegal; Tandem Mass Spectrometry	2022
Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:4 Topics: Acyl Coenzyme A; Atorvastatin; Drug Costs; Dyslipidemias; Female; Formularies as Topic; Health Expenditures; Heptanoic Acids; Humans; Insurance Claim Review; Male; Managed Care Programs; Medicaid; Middle Aged; Pyrroles; Retrospective Studies; Therapeutic Equivalency	2006

Article

Year

Ameliorations in dyslipidemia and atherosclerotic plaque by the inhibition of HMG-CoA reductase and antioxidant potential of phytoconstituents of an aqueous seed extract of Acacia senegal (L.) Willd in rabbits.

PloS one, 2022, Volume: 17, Issue:3

Topics: Acacia; Acyl Coenzyme A; Animals; Antioxidants; Chromatography, Liquid; Dyslipidemias; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Molecular Docking Simulation; Plant Extracts; Plaque, Atherosclerotic; Rabbits; Senegal; Tandem Mass Spectrometry

2022

Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization.

Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:4

Topics: Acyl Coenzyme A; Atorvastatin; Drug Costs; Dyslipidemias; Female; Formularies as Topic; Health Expenditures; Heptanoic Acids; Humans; Insurance Claim Review; Male; Managed Care Programs; Medicaid; Middle Aged; Pyrroles; Retrospective Studies; Therapeutic Equivalency

2006